What are the responsibilities and job description for the Director, Medical Communications position at DBV Technologies?
Description
The Director, Medical Communications is a member of the Medical Affairs team responsible for supporting the successful execution of the medical communications plan in support of DBV’s overall strategic direction for the VIASKIN Patch platform. This includes execution of the global publication strategy and medical education plan, with a focus on the VIASKIN Peanut Patch. This role ensures that scientific data for VIASKIN® Peanut Patch and other pipeline candidates are communicated with clinical precision and strategic alignment across the global medical community. Serving as a key link between internal stakeholders (Clinical Operations, Biostats, MSLs, etc) and external partners (HCPs, journals, vendors), the Director ensures all communications are scientifically rigorous, compliant with global standards (GPP/ICMJE), and delivered on schedule.
Location: Warren, New Jersey - 3 days on site
Salary Range: 180-195K
Key Responsibilities
Publication Development
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
The Director, Medical Communications is a member of the Medical Affairs team responsible for supporting the successful execution of the medical communications plan in support of DBV’s overall strategic direction for the VIASKIN Patch platform. This includes execution of the global publication strategy and medical education plan, with a focus on the VIASKIN Peanut Patch. This role ensures that scientific data for VIASKIN® Peanut Patch and other pipeline candidates are communicated with clinical precision and strategic alignment across the global medical community. Serving as a key link between internal stakeholders (Clinical Operations, Biostats, MSLs, etc) and external partners (HCPs, journals, vendors), the Director ensures all communications are scientifically rigorous, compliant with global standards (GPP/ICMJE), and delivered on schedule.
Location: Warren, New Jersey - 3 days on site
Salary Range: 180-195K
Key Responsibilities
Publication Development
- Support the timely drafting, reviewing and editing of impactful scientific abstracts, posters, oral presentations, and manuscripts
- Interpret and organize complex scientific and clinical data, including the review of clinical trial outputs and statistical analysis data to identify appropriate data for publication
- Support the development of external educational medical content, such as slide decks, videos, and printed materials to ensure scientific accuracy and alignment with strategic direction
- Build and maintain internal educational resources, such Scientific Platform and training materials, through regular updates and in alignment with cross-functional teams
- Partner with the MSL team to develop internal training materials and external resources to ensure field readiness
- Assist with other Medical Affairs and company projects, as needed
- Survey and interpret scientific literature and provide ongoing written assessments to internal stakeholders
- Advise on necessary updates to educational content based on insights gathered through MSL team and advisor feedback
- Ensure compliance with all legal, regulatory and DBV requirements
- Provide oversight and actionable feedback to medical communication agencies and independent contractors
- Assist in building and maintaining project-specific budgets and timelines
- Identify and screen appropriate vendors; evaluate and recommend proposals for approval
- Advanced medical or scientific degree (MD, PhD, PharmD)
- Minimum 5 years of experience within a pharmaceutical or biotech company or medical communications agency
- Demonstrated experience in publication planning and execution, as well as development of medical education materials
- Experience working directly with external experts (KOLs) and scientific authors to facilitate the publication process
- Experience in allergy / immunology preferred
- Curiosity: Keep on exploring uncharted territories. Always ask “why?” and more importantly “why not?”,
- Courage: Take smart risks, mentor each other to always do better & be accountable for our choices, our opinions, and our actions,
- Collaboration: Teamwork and spirit. Support each other and be equally involved in the achievement of our common goals,
- Credibility: Be transparent, follow through and build trust. Educate ourselves about our unique technology.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.